Sequoia Financial Advisors LLC grew its stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 34.5% in the fourth ...

Altimmune (NASDAQ:ALT – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research ...

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ...

Shares of Altimmune Inc. are down more than 23% this year, but that has not deterred retail investors from losing hope in the ...

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Bullish option flow detected in Altimmune (ALT) with 8,561 calls trading, 3x expected, and implied vol increasing almost 4 points to 114.21%.

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...